Pure Global

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation - Trial NCT06386146

Access comprehensive clinical trial information for NCT06386146 through Pure Global AI's free database. This Phase 1/2 trial is sponsored by Jacobio Pharmaceuticals Co., Ltd. and is currently Not yet recruiting. The study focuses on Solid Tumors. Target enrollment is 144 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.

Free Database
Powered by Pure Global AI
840K+ Trials
NCT06386146
Phase 1/2
Not yet recruiting
drug
Trial Details
ClinicalTrials.gov • NCT06386146
View on ClinicalTrials.gov
Pure Global
DJ Fang

DJ Fang

MedTech Regulatory Expert

Need help with 30+ markets registration?

Pricing
JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation
A Phase 1/2a, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-30355 in Adult Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Study Focus

Solid Tumors

JAB-30355

Interventional

drug

Sponsor & Location

Jacobio Pharmaceuticals Co., Ltd.

Timeline & Enrollment

Phase 1/2

Jul 01, 2024

Jul 01, 2027

144 participants

Primary Outcome

Dose limiting toxicity (DLT),Number of participants with adverse events

Summary

This study is to evaluate the efficacy and safety of JAB-30355 in adult participants with
 advanced solid tumors harboring TP53 Y220C mutation.

ICD-10 Classifications

Malignant neoplasm: Connective and soft tissue, unspecified
Malignant neoplasm of other connective and soft tissue
Carcinoma in situ, unspecified
Malignant neoplasms
Malignant neoplasm: Parametrium

Data Source

ClinicalTrials.gov

NCT06386146

Non-Device Trial